Glioma cancer stem cells and tumor-derived mesenchymal stem cells: role and crosstalk in human gliomas.
Ken Aldape, MD, Fred Lang, MD
- The current marker for isolating glioma cancer stem cells (GCSCs), CD133, has proven to be suboptimal, and better markers are needed so that precise targeting of GCSCs can be achieved; the Aldape lab identified a new protein, podoplanin (pdpn), which more precisely identifies GCSCs compared with CD133.
- Other evidence indicates that GSCSs alone do not account for all the features of GBMs, particularly vascular proliferation; the Aldape/Lang lab has shown that other recruited cells, particularly human mesenchymal stem cells (hMSCs), provide critical contributions to GBM formation and increase therapeutic resistance of GCSCs.
- Investigators propose to test the hypothesis that a) GBMs consist of GCSCs, which are the tumor initiating cells, and tumor-derived hMSC, which increase the aggressiveness of GBMs by providing the proper environment for tumor growth, and b) the cross-talk between these cell types contributes to the therapeutic resistance of gliomas.